Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Testicular Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Seminoma 1Oropharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Medulloblastoma 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Hearing Loss 1Carcinoma 1

Interventions

Magnetic Resonance Spectroscopy 3Cisplatin 3Carboplatin 3Platinum 2Methods 2Fluorodeoxyglucose F18 2FAPI-46 2Etoposide 2veliparib 1trastuzumab deruxtecan 1sodium thiosulfate 1brodalumab 1Taxes 1Surveys and Questionnaires 1Specimen Handling 1Psychology, Positive 1Psychiatric Nursing 1Physical Therapy Modalities 1Paclitaxel 1Neoadjuvant Therapy 1Mental Status and Dementia Tests 1Interviews as Topic 1Hearing 1Exercise 1Educational Status 1Costs and Cost Analysis 1Blood Specimen Collection 1Bleomycin 1Aspirin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Testicular Neoplasms × Hearing × 1 year × Clear all
NCT07218913 2026-04-17

Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors

City of Hope Medical Center

Phase 1 Recruiting
44 enrolled
Genitourinary

Testicular Neoplasms, Seminoma, Hearing Loss

Data powered by HemOnc (CC BY 4.0) Colophon âš¡